Akari Therapeutics, Plc (AKTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Akari Therapeutics, Plc (AKTX) Healthcare & Pipeline Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company based in London, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product, nomacopan, a second-generation complement inhibitor, targets conditions like paroxysmal nocturnal hemoglobinuria and Guillain-Barré syndrome, positioning the company in the competitive biotechnology sector.

What Is the Investment Thesis for AKTX?

Akari Therapeutics, Plc presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The core value driver is the successful development and commercialization of nomacopan. Positive clinical trial results for indications like PNH, GBS, HSCT-TMA, and BP could significantly increase the company's valuation. Key catalysts include the progression of nomacopan through clinical trial phases and potential partnerships with larger pharmaceutical companies. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for additional funding. With a small market cap, AKTX is highly sensitive to news flow and market sentiment. The company's success hinges on the clinical and commercial viability of nomacopan.

Based on FMP financials and quantitative analysis

AKTX Key Highlights

Akari Therapeutics focuses on developing therapies for autoimmune and inflammatory diseases.

• Nomacopan, a second-generation complement inhibitor, is the company's lead product candidate.
• The company is targeting indications such as paroxysmal nocturnal hemoglobinuria (PNH) and Guillain-Barré syndrome (GBS).
• Akari Therapeutics is based in London, United Kingdom.
• The company has a small team of 8 employees.

Who Are AKTX's Competitors?

AKTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AKTX's Key Strengths?

Novel therapeutic approach targeting the complement system.

• Lead product candidate with potential for multiple indications.
• Experienced management team with expertise in drug development.
• Orphan drug designation opportunities.

What Are AKTX's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources and reliance on external funding.
• Small team size.
• High risk of clinical trial failure.

What Could Drive AKTX Stock Higher?

Clinical trial results for nomacopan in paroxysmal nocturnal hemoglobinuria (PNH).

• Clinical trial results for nomacopan in Guillain-Barré syndrome (GBS).
• Potential partnerships with larger pharmaceutical companies.
• Advancements in drug delivery technologies for nomacopan.

What Are the Key Risks for AKTX?

Financial-distress signal — its Altman Z-Score of -12.89 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for nomacopan.
• Regulatory hurdles and lengthy approval processes.
• Limited financial resources and reliance on external funding.
• Competition from established pharmaceutical companies.
• Pricing pressures and reimbursement challenges.

What Are the Growth Opportunities for AKTX?

• Expansion into New Therapeutic Areas: Akari Therapeutics has the opportunity to expand the application of nomacopan into additional autoimmune and inflammatory diseases. The complement system plays a role in a wide range of conditions, presenting potential for nomacopan to address unmet needs in areas beyond its current targets. This expansion could significantly increase the market opportunity for the drug, although it would require further research and clinical trials. The timeline for this growth opportunity is dependent on the success of ongoing trials and the identification of suitable new indications.
• Partnerships and Collaborations: Akari Therapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of nomacopan. Collaborations can provide access to additional funding, expertise, and resources, increasing the likelihood of successful drug development and market penetration. These partnerships could involve licensing agreements, joint ventures, or co-development arrangements. The timeline for securing such partnerships is uncertain but could materialize within the next 2-3 years, depending on clinical trial progress and market interest.
• Geographic Expansion: Akari Therapeutics can expand its geographic reach by seeking regulatory approval and commercializing nomacopan in new markets. The company is currently based in the United Kingdom, but it could target markets in Europe, North America, and Asia. This expansion would require navigating different regulatory frameworks and establishing distribution networks. The timeline for geographic expansion depends on regulatory approval timelines and the availability of resources to support commercialization efforts.
• Orphan Drug Designation: Akari Therapeutics can leverage orphan drug designation for nomacopan in specific indications to gain regulatory and commercial advantages. Orphan drug designation provides incentives such as market exclusivity, tax credits, and reduced regulatory fees. This can enhance the attractiveness of nomacopan to investors and potential partners. The timeline for obtaining orphan drug designation depends on the specific indication and the regulatory requirements in each jurisdiction.
• Advancements in Drug Delivery: Akari Therapeutics can explore advancements in drug delivery technologies to improve the efficacy and patient experience of nomacopan. This could involve developing new formulations or delivery methods that enhance drug absorption, reduce side effects, or improve patient compliance. Advancements in drug delivery could also extend the patent life of nomacopan and create new market opportunities. The timeline for implementing these advancements depends on the availability of suitable technologies and the resources to support research and development efforts.

What Are AKTX's Competitive Advantages?

• Patented drug formulations and therapeutic methods.
• Clinical data supporting the efficacy and safety of nomacopan.
• Orphan drug designation for specific indications.
• Expertise in complement inhibition and drug development.

What Does AKTX Do?

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for autoimmune and inflammatory diseases. The company's primary focus is on its lead product candidate, nomacopan, a second-generation complement inhibitor designed to address a range of severe inflammatory and prothrombotic conditions. Nomacopan works by inhibiting the inflammatory and prothrombotic activities mediated by the complement system, a crucial part of the immune system. Akari Therapeutics is headquartered in London, United Kingdom. The company is working to advance nomacopan through clinical trials, targeting indications with significant unmet medical needs, such as paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). These conditions represent areas where current treatment options are limited or have significant side effects, highlighting the potential for nomacopan to offer improved outcomes for patients. Akari Therapeutics is managed by a small team of 8 employees.

What Products and Services Does AKTX Offer?

• Develops therapies for autoimmune and inflammatory diseases.
• Focuses on complement inhibition to treat disease.
• Lead product candidate is nomacopan.
• Targets paroxysmal nocturnal hemoglobinuria (PNH).
• Targets Guillain-Barré syndrome (GBS).
• Targets hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
• Targets bullous pemphigoid (BP).

How Does AKTX Make Money?

• Develops and patents novel therapeutic drugs.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved drugs directly or through partnerships.

What Industry Does AKTX Operate In?

Akari Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for autoimmune and inflammatory disease therapies is substantial, driven by an aging population and increasing prevalence of these conditions. Companies like Akari Therapeutics face competition from established pharmaceutical giants and other biotech firms developing novel therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies. The biotechnology industry is subject to evolving regulatory landscapes and pricing pressures.

Who Are AKTX's Key Customers?

• Patients suffering from autoimmune and inflammatory diseases.
• Hospitals and clinics that administer treatments.
• Specialty pharmacies that dispense medications.
• Healthcare providers who prescribe treatments.

Company Profile

Akari Therapeutics, Plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Abizer Gaslightwala. AKTX has traded publicly since 2014.

How Akari Therapeutics, Plc Is Valued

Akari Therapeutics, Plc carries a market capitalization of $8.92M, placing it in the micro-cap category. Relative to its peer group, AKTX's quantitative score of 27/100 is below the peer average of 60/100.

Key Financial Metrics

Return on assets is -82.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -57.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.

Akari Therapeutics, Plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.89 places it in the distress zone, a signal of elevated financial risk.

Akari Therapeutics, Plc has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 13659.1% below estimates on average.

Wall Street analysts project Akari Therapeutics, Plc revenue of about $9.6M for fiscal 2026, with EPS near $-8.01.

AKTX Financials

AKTX Latest News

AKTX Analyst Consensus

AKTX MoonshotScore

Common Questions About AKTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources